Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease.
Catarina Tristão-Pereira, Daniel Vasquez, Jorge Alcina, Ana Baena, David Aguillon, Paula Ospina Lopera, Natalia Londono, Claudia Ramos, Lusiana Martinez, Sergio Alvarez and 9 more
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Nerve Growth (NGF) Factor Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's DiseaseR01AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI David Fernando Aguillon, A CLAUDIO CUELLO · 2025 to 2026
$1.3M
NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG077627
6 · The paper itself
Abstract
introductionThe Mild Behavioral Impairment Checklist (MBI-C) captures neuropsychiatric symptoms in individuals at risk of dementia. In this study, we examined MBI-C scores in autosomal dominant Alzheimer's disease (ADAD).
methodsWe included 83 cognitively unimpaired presenilin-1 E280A mutation carriers and 114 non-carriers with MBI-C, obfjective cognition, and subjective cognitive decline (SCD) assessments. Study sub-samples underwent neuroimaging to assess Alzheimer's disease (AD) pathology and neurodegeneration.
resultsMBI-C total scores were greater in carriers than non-carriers ( DISCUSSION: Our study reveals that mild behavioral impairment symptoms may emerge before cognitive decline in ADAD and supports the MBI-C as a tool for detecting early behavioral changes linked to AD pathology and identifying at-risk individuals for clinical trials and early intervention.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease. · full record | OpenQuestion